GC Green Cross, Announces Immunoglobulin 'Aliglo' Thrombosis Research at US Conference

[Financial News] GC Green Cross announced on the 17th that its US subsidiary, GC Biopharma USA, presented research results related to the viscosity of immunoglobulin preparations at the '2025 International Society on Thrombosis and Haemostasis (ISTH)' held in New Jersey, USA.

Immunoglobulin preparations are used in the treatment of immune diseases and are known to increase blood viscosity after administration, which can increase the risk of thromboembolism.
This presentation measured the viscosity of five types of immunoglobulin preparations used in the market under various temperature conditions from 4℃ to 25℃, and all products showed a tendency for viscosity to decrease as the temperature increased. Accordingly, the possibility of reducing viscosity-related risks when administered at room temperature (25℃) was suggested.
The study applied a standardized measurement method for immunoglobulin concentration to quantitatively compare the viscosity between products. The research team emphasized that the physical properties of immunoglobulin preparations, such as viscosity and purity, can be important safety indicators to consider when selecting products for patients at high risk of thrombosis.
Susan Strasters, head of clinical education at GC Biopharma USA, who presented this data, said, “Although these are preliminary results, there is a possibility of differences in viscosity between products, and further research is needed,” adding, “This could be a clinically important clue in selecting suitable preparations for patients at high risk of thrombosis.”
This study was presented through a poster session under the title 'Investigation into the Viscosity of Commercial IG Preparations'.
The analysis included immunoglobulin preparations distributed in the US, including GC Green Cross's Aliglo.
Aliglo is a 10% immunoglobulin product approved by the US FDA for the treatment of primary immunodeficiency (PI) in adults aged 17 and older. GC Green Cross, which has 50 years of expertise in the field of plasma fractionation, currently supplies various products to over 50 countries.

vrdw88@fnnews.com Kang Jung-mo Reporter